Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy

CONCLUSIONS: In eBC patients treated with NAC, taking into account HR expression subtype and other current clinicopathological features, HER2-low tumors did not appear to have different chemosensitivity or prognosis, compared to their HER2-0 counterparts.PMID:37561255 | DOI:10.1007/s12282-023-01490-1

Source: Breast Cancer - August 10, 2023 Category: Cancer & Oncology Authors: Silvia Mihaela Ilie Nathalie Briot Guillaume Constantin Nicolas Roussot Alis Ilie Anthony Bergeron Laurent Arnould Fran çoise Beltjens Isabelle Desmoulin Didier Mayeur Cour èche Kaderbhai Audrey Hennequin Cl émentine Jankowski Marie Martine Padeano Hel Source Type: research